IL13 and asthma: Indeed, when used as an add-on strategy in patients with mild to moderate asthma, subcutaneous AIT (SCIT) helps reduce the use of inhaled β2 agonists [43] and decreases type 2 cytokine release (IL5 and IL-13) by PBMCs [44].